User:Mr. Ibrahem/Conivaptan

Mr. Ibrahem/Conivaptan
Clinical data
Trade names	Vaprisol
Other names	YM 087
AHFS/Drugs.com	Monograph
License data	US DailyMed: Conivaptan;
Routes of; administration	Intravenous
Drug class	Vasopressin receptor antagonist.
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	N/A
Identifiers
	IUPAC name N-(4-((4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide;
Chemical and physical data
Formula	C32H26N4O2
Molar mass	498.586 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccccc1-c2ccccc2C(=O)Nc3ccc(cc3)C(=O)N4c5ccccc5-c6[nH]c(C)nc6CC4;
	InChI InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) ; Key:IKENVDNFQMCRTR-UHFFFAOYSA-N ;
	(what is this?) (verify)

Conivaptan, sold under the brand name Vaprisol, is a medication used to treat low sodium in those who either have normal or high total body fluid.^[1] While it may improve lab values, it is unclear if it improves outcomes.^[1] It is given by injection into a vein.^[1]

Common side effects include pain at the site of injection, fever, low potassium, headache, and low blood pressure with standing.^[1] Other side effects may include osmotic demyelination syndrome if sodium is corrected too rapidly.^[2] Safety in pregnancy is unclear as is safety in heart failure.^[2] It is a vasopressin receptor antagonist.^[1]

Conivaptan was approved for medical use in the United States in 2005.^[1] It has not been approved in the United Kingdom as of 2011.^[3] In the United States it costs nearly 1,000 USD per 20 mg dose as of 2022.^[4]

References

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "DailyMed - VAPRISOL DEXTROSE IN PLASTIC CONTAINER- conivaptan hydrochloride injection, solution". dailymed.nlm.nih.gov. Archived from the original on 21 April 2021. Retrieved 6 January 2022.
^ ^a ^b "Conivaptan Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 7 January 2022.
^ Gardner, Roy S.; Clark, Andrew L.; Dargie, Henry (14 July 2011). Oxford Textbook of Heart Failure. OUP Oxford. p. 154. ISBN 978-0-19-957772-9. Archived from the original on 11 January 2022. Retrieved 7 January 2022.
^ "Vaprisol Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 April 2021. Retrieved 7 January 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "DailyMed - VAPRISOL DEXTROSE IN PLASTIC CONTAINER- conivaptan hydrochloride injection, solution". dailymed.nlm.nih.gov. Archived from the original on 21 April 2021. Retrieved 6 January 2022.

[AHFS2022-2] "Conivaptan Monograph for Professionals". Drugs.com. Archived from the original on 23 January 2021. Retrieved 7 January 2022.

[3] Gardner, Roy S.; Clark, Andrew L.; Dargie, Henry (14 July 2011). Oxford Textbook of Heart Failure. OUP Oxford. p. 154. ISBN 978-0-19-957772-9. Archived from the original on 11 January 2022. Retrieved 7 January 2022.

[4] "Vaprisol Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 April 2021. Retrieved 7 January 2022.

[1]

[2]

[3]

[4]